Cargando…

Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome

In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zongping, Deng, Jichun, Yan, Yong, Li, Min, Chen, Chanjuan, Chen, Chao, Zhao, Sicong, Song, Tao, Liu, Tong, Wen, Xin, Yao, Yuhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061238/
https://www.ncbi.nlm.nih.gov/pubmed/29948970
http://dx.doi.org/10.1007/s12672-018-0335-8
_version_ 1783342180629217280
author Chen, Zongping
Deng, Jichun
Yan, Yong
Li, Min
Chen, Chanjuan
Chen, Chao
Zhao, Sicong
Song, Tao
Liu, Tong
Wen, Xin
Yao, Yuhong
author_facet Chen, Zongping
Deng, Jichun
Yan, Yong
Li, Min
Chen, Chanjuan
Chen, Chao
Zhao, Sicong
Song, Tao
Liu, Tong
Wen, Xin
Yao, Yuhong
author_sort Chen, Zongping
collection PubMed
description In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment to evaluate the effects of various treatment methods on MetS. We analyzed data of 1162 PCa patients, whether or not diagnosed with MetS, and changes in MetS patients after PCa treatment. Data of lower urinary tract symptoms, C-reactive protein (CRP), platelet distribution width (PDW), prostate-specific antigen (PSA), Gleason score, clinical stage, treatment methods, and progressive incidents were evaluated using logistic regression according to MetS diagnosis. The results showed significant differences in the prevalence of MetS before (17.38%) and after (23.67%) PCa treatment (P < 0.001). Bad diet, living habits, and prostate cancer treatment were considered as risk factors for MetS (OR = 1.731, 95%CI 1.367–2.193, P < 0.001). Radical prostatectomy (RP), androgen deprivation therapy including surgical castration and medical castration, iodine-125 seed brachytherapy ((125)I limited), and chemotherapy were independent risk factors of MetS. The MetS incidence rates after treatment in ADT+(125)I limited+chemotherapy compared to RP+TURP+EBRT were statistically significant at the corresponding risk grade (all P < 0.001). After treatment, the occurrence rates of progressive incidences were higher in MetS-PCa patients compared to non-MetS-PCa patients (all P < 0.001). So, the findings suggested that among PCa patients, multiple factors contribute to the occurrence of MetS, and PCa treatment is one among them. ADT+(125)I limited+chemotherapy may be the most influential treatment for MetS.
format Online
Article
Text
id pubmed-6061238
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-60612382018-08-09 Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome Chen, Zongping Deng, Jichun Yan, Yong Li, Min Chen, Chanjuan Chen, Chao Zhao, Sicong Song, Tao Liu, Tong Wen, Xin Yao, Yuhong Horm Cancer Original Paper In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment to evaluate the effects of various treatment methods on MetS. We analyzed data of 1162 PCa patients, whether or not diagnosed with MetS, and changes in MetS patients after PCa treatment. Data of lower urinary tract symptoms, C-reactive protein (CRP), platelet distribution width (PDW), prostate-specific antigen (PSA), Gleason score, clinical stage, treatment methods, and progressive incidents were evaluated using logistic regression according to MetS diagnosis. The results showed significant differences in the prevalence of MetS before (17.38%) and after (23.67%) PCa treatment (P < 0.001). Bad diet, living habits, and prostate cancer treatment were considered as risk factors for MetS (OR = 1.731, 95%CI 1.367–2.193, P < 0.001). Radical prostatectomy (RP), androgen deprivation therapy including surgical castration and medical castration, iodine-125 seed brachytherapy ((125)I limited), and chemotherapy were independent risk factors of MetS. The MetS incidence rates after treatment in ADT+(125)I limited+chemotherapy compared to RP+TURP+EBRT were statistically significant at the corresponding risk grade (all P < 0.001). After treatment, the occurrence rates of progressive incidences were higher in MetS-PCa patients compared to non-MetS-PCa patients (all P < 0.001). So, the findings suggested that among PCa patients, multiple factors contribute to the occurrence of MetS, and PCa treatment is one among them. ADT+(125)I limited+chemotherapy may be the most influential treatment for MetS. Springer US 2018-06-09 /pmc/articles/PMC6061238/ /pubmed/29948970 http://dx.doi.org/10.1007/s12672-018-0335-8 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Chen, Zongping
Deng, Jichun
Yan, Yong
Li, Min
Chen, Chanjuan
Chen, Chao
Zhao, Sicong
Song, Tao
Liu, Tong
Wen, Xin
Yao, Yuhong
Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title_full Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title_fullStr Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title_full_unstemmed Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title_short Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
title_sort risk analysis of prostate cancer treatments in promoting metabolic syndrome development and the influence of increased metabolic syndrome on prostate cancer therapeutic outcome
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061238/
https://www.ncbi.nlm.nih.gov/pubmed/29948970
http://dx.doi.org/10.1007/s12672-018-0335-8
work_keys_str_mv AT chenzongping riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT dengjichun riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT yanyong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT limin riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT chenchanjuan riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT chenchao riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT zhaosicong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT songtao riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT liutong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT wenxin riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome
AT yaoyuhong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome